Theratope® vaccine (STn-KLH)

Publisher Website
Google Scholar
Abstract
Active specific immunotherapy (ASI) is a promising approach to treating cancer. Numerous studies in the laboratory have demonstrated that various cancer vaccines can stimulate antibody and cell mediated immune responses against tumour-associated antigens [1-9]. Yet few studies have demonstrated convincing clinical responses. Sialyl-Tn (STn) is a carbohydrate associated with the MUC1 mucin on a number of human cancer cells and is associated with more aggressive disease. Consequently, STn is an ideal candidate for ASI therapy. Theratope® vaccine is a cancer vaccine that was designed by Biomira, Inc. (Edmonton, Alberta, Canada) by incorporating a synthetic STn antigen that emulates the carbohydrate seen on human tumours. The clinical trials conducted to date with Theratope® vaccine are outlined in this report. Overall, Theratope® vaccine has been well-tolerated with minimal toxicity. The most common side effects have been induration and erythema at the site of injections. Both in a non-transplant setting fol...

This publication has 16 references indexed in Scilit: